SCHEMBL2940413

SCHEMBL2940413

O=C(Oc1ccccc1)c1cnccc1CN1CC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 4/20 0.39
PPARA Q07869 4/20 0.39
ENPP2 Q13822 2/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
NTRK1 P04629 1/20 0.35
PPARG P37231 2/20 0.35
FLT1 P17948 1/20 0.35
KDR P35968 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.34
LIPE Q05469 3/20 0.34
HPGD P15428 1/20 0.34
PLA2G4A P47712 1/20 0.34
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939834 0.90 PPARD (0.42) PPARDPPARAENPP2KDM5AKDM4C
SCHEMBL2934064 0.89 IGF1R (0.37) PPARDPPARAENPP2KMT2APOLB
SCHEMBL2939214 0.88 IGF1R (0.38) PPARDPPARAENPP2KMT2APOLB
SCHEMBL2992187 0.87 ROCK2 (0.40) PPARDPPARAENPP2KDM5AKDM4C
SCHEMBL2939402 0.87 KDR (0.46) SMN1; SMN2FLT1KDRNAMPT
SCHEMBL2940517 0.86 PPARD (0.41) PPARDPPARAPOLBPPARGTAS2R8
SCHEMBL3733210 0.86 PPARD (0.41) PPARDPPARAPOLBNTRK1PPARG
SCHEMBL2941399 0.86 GSK3A (0.37) PPARDPPARAENPP2KMT2AKDM5A
SCHEMBL2940504 0.85 PPARD (0.38) PPARDPPARAENPP2PPARGTAS2R8
SCHEMBL2941042 0.85 KMT2A (0.41) PPARDPPARAENPP2KMT2ACYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PPARD 3189/4885PPARA 4338/4885ENPP2 3905/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA PPARD 3572/4885PPARA 4692/4885ENPP2 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.